{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-071383","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2026-06-08T20:10:52+00:00","discovered_at":"2026-06-08T20:12:00.309978+00:00","generated_at":"2026-06-08T20:19:19.857306+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Century Therapeutics presents preclinical data for CNTY-813; glucose control >8 months, IND on track for Q4 2026","bullets":["CNTY-813 maintained glucose control for >8 months in diabetic mouse models without immunosuppression.","No tumorigenesis observed in >140 mice with >1 billion cells infused over 3 months follow-up.","Allo-Evasion 5.0 edits provided protection from NK cells, antibody-mediated phagocytosis, and maintained insulin secretion in humanized mouse model.","Phase 1 manufacturing process established; consistent product quality across 11 samples from GMP Master Cell Bank.","IND submission on track for Q4 2026; initial clinical data expected in 2H 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-071383","json":"https://secwatch.observer/filing/0001104659-26-071383.json","markdown":"https://secwatch.observer/filing/0001104659-26-071383.md","text":"https://secwatch.observer/filing/0001104659-26-071383.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465926071383/0001104659-26-071383-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465926071383/tm2617028d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T20:19:19.857306+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}